TY - JOUR
T1 - Thienopyridine reloading in clopidogrel-loaded patients undergoing percutaneous coronary interventions
T2 - The PRAISE study
AU - Guo, Long Zhe
AU - Kim, Moo Hyun
AU - Shin, Eun Seok
AU - Ann, Soe Hee
AU - De Jin, Cai
AU - Cho, Young Rak
AU - Park, Jong Sung
AU - Park, Kyungil
AU - Park, Tae Ho
AU - Lee, Michael S.
AU - Serebruany, Victor L.
PY - 2016/11/1
Y1 - 2016/11/1
N2 - Objective The impact of thienopyridine reloading on clinical outcomes, and residual high platelet reactivity (HPR) is unclear. We sought to compare the HRP-related effect of prasugrel and clopidogrel reloading in the already clopidogrel-loaded patients undergoing percutaneous coronary intervention (PCI). Materials and methods In this prospective, two-center, randomized, open-label study, patients with HPR who had undergone PCI after a clopidogrel (300–600 mg) loading dose (LD) were enrolled. Among screened (n = 153), HPR was determined in seventy-six patients, who were randomized to either repeated clopidogrel (300 mg LD, followed by 75 mg MD daily) or prasugrel (20 mg LD, followed by 5 mg MD daily). The primary endpoint was HPR at 24 h after PCI, as determined by the VerifyNow assay. The rates of sustained high and low platelet reactivity, periprocedural myocardial injury (PMI) and 30-day clinical outcomes were also assessed. Results Higher inhibition of platelet reactive units (PRU) was observed in the prasugrel group than after clopidogrel reloading (Pre-PCI: 284.4 ± 32.0 vs 279.5 ± 32.5, p = 0.504; Post-PCI: 100.0 ± 67.0 vs 202.9 ± 65.8, p < 0.001; 30 days: 170.8 ± 69.8 vs 215.1 ± 62.4, p = 0.007). There were less HRP post-PCI after prasugrel compared with the clopidogrel group (2.7 vs 36.1%, p < 0.001). However, reloading with prasugrel did not reduce PMI compared to clopidogrel (36.8% vs 39.5%, p = 0.813). Conclusion Prasugrel reloading led to a greater reduction in HPR, but similar with clopidogrel PMI in post-PCI patients. Larger randomized evidence is needed for optimization of loading strategies with thienopyridines. Clinical Trial Registration Information: NCT01609647.
AB - Objective The impact of thienopyridine reloading on clinical outcomes, and residual high platelet reactivity (HPR) is unclear. We sought to compare the HRP-related effect of prasugrel and clopidogrel reloading in the already clopidogrel-loaded patients undergoing percutaneous coronary intervention (PCI). Materials and methods In this prospective, two-center, randomized, open-label study, patients with HPR who had undergone PCI after a clopidogrel (300–600 mg) loading dose (LD) were enrolled. Among screened (n = 153), HPR was determined in seventy-six patients, who were randomized to either repeated clopidogrel (300 mg LD, followed by 75 mg MD daily) or prasugrel (20 mg LD, followed by 5 mg MD daily). The primary endpoint was HPR at 24 h after PCI, as determined by the VerifyNow assay. The rates of sustained high and low platelet reactivity, periprocedural myocardial injury (PMI) and 30-day clinical outcomes were also assessed. Results Higher inhibition of platelet reactive units (PRU) was observed in the prasugrel group than after clopidogrel reloading (Pre-PCI: 284.4 ± 32.0 vs 279.5 ± 32.5, p = 0.504; Post-PCI: 100.0 ± 67.0 vs 202.9 ± 65.8, p < 0.001; 30 days: 170.8 ± 69.8 vs 215.1 ± 62.4, p = 0.007). There were less HRP post-PCI after prasugrel compared with the clopidogrel group (2.7 vs 36.1%, p < 0.001). However, reloading with prasugrel did not reduce PMI compared to clopidogrel (36.8% vs 39.5%, p = 0.813). Conclusion Prasugrel reloading led to a greater reduction in HPR, but similar with clopidogrel PMI in post-PCI patients. Larger randomized evidence is needed for optimization of loading strategies with thienopyridines. Clinical Trial Registration Information: NCT01609647.
KW - Acute coronary syndrome
KW - Clopidogrel
KW - Coronary interventions
KW - Platelet reactivity
KW - PRAISE
KW - Prasugrel
UR - http://www.scopus.com/inward/record.url?scp=84981730229&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84981730229&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2016.08.027
DO - 10.1016/j.ijcard.2016.08.027
M3 - Article
C2 - 27517654
AN - SCOPUS:84981730229
SN - 0167-5273
VL - 222
SP - 639
EP - 644
JO - International Journal of Cardiology
JF - International Journal of Cardiology
ER -